TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks. The company is developing its lead TCR-T therapy candidates, TSC-100 and TSC-101, in an early-stage study for treating patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. TScan is also developing TCR-T therapy candidates for treating various solid tumors. The growing optimism about the company's pipeline candidates might have driven the recent share price rally. This company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of -16.7%. Revenues are expected to be $2.86 million, down 26.4% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.MarketBeat
- City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
TCRX
Earnings
- 11/12/24 - Beat
TCRX
Sec Filings
- 12/16/24 - Form 4
- 12/10/24 - Form 8-K
- 11/21/24 - Form 8-K
- TCRX's page on the SEC website